Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.74 |
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.74 |
| ▸ | HTT | P42858 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | TP53 | P04637 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5851284 | 0.91 | MEN1 (0.73) | MEN1P2RY12HTTTSHRSMN1; SMN2 | |
| SCHEMBL12789922 | 0.85 | P2RY12 (1.00) | MEN1P2RY12HTTTSHRSMN1; SMN2 | |
| SCHEMBL5850718 | 0.85 | MEN1 (0.65) | MEN1P2RY12HTTTSHRSMN1; SMN2 | |
| SCHEMBL7060963 | 0.84 | MEN1 (0.78) | MEN1P2RY12HTTTSHRSMN1; SMN2 | |
| SCHEMBL5849178 | 0.84 | MEN1 (0.68) | MEN1P2RY12HTTTSHRSMN1; SMN2 | |
| SCHEMBL7048532 | 0.83 | MEN1 (0.67) | MEN1P2RY12HTTTSHRSMN1; SMN2 | |
| SCHEMBL5849207 | 0.83 | MEN1 (0.76) | MEN1P2RY12HTTTSHRSMN1; SMN2 | |
| SCHEMBL5849200 | 0.83 | P2RY12 (1.00) | MEN1P2RY12HTTTSHRSMN1; SMN2 | |
| SCHEMBL5849305 | 0.82 | P2RY12 (0.92) | MEN1P2RY12HTTTSHRSMN1; SMN2 | |
| SCHEMBL5851426 | 0.82 | P2RY12 (0.75) | MEN1P2RY12HTTTSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115741-B2 | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds | ALEXION PHARMACEUTICALS, INC. | 2006-10-03 | — | — | US | disclosed |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153556-A1 | Piperazine and homopiperazine compounds | HAMP, MPL, F2 | MEN1 2603/4885P2RY12 111/4885HTT 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.